Novel Drug Delivery Methods and Treatment Approaches for Retinal Diseases : Episode 8

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

January 31, 2025

By Aleksandra Rachitskaya, MD
Jordan Graff, MD, FACS

Opinion

Video

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

EP: 1.Overview of Novel Treatments for Retinal Vascular Diseases

EP: 2.Overview and Benefits of Port Delivery System with Ranibizumab

EP: 3.Patient Selection For Port Delivery System

EP: 4.Considerations for Surgical Implant of the Port Delivery System and Refill Process

EP: 5.Key Steps in the Surgical Implantation of the Port Delivery System

EP: 6.Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

EP: 7.Adverse Events of the Port Delivery System and Addressing Challenges with Adoption

Now Viewing

EP: 8.Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!